Navigation Links
Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Amgen (NASDAQ:AMGN), today announced final results from a pivotal Phase 3 trial which showed that Vectibix(TM) (panitumumab), a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFr), prolonged progression-free survival (PFS) compared to best supportive care (BSC) in metastatic colorectal cancer patients who had failed fluoropyrimidine, irinotecan, and oxaliplatin containing chemotherapy regimens. The results were published in the May issue of the Journal of Clinical Oncology.

"Medical advances in the treatment of first- and second-line colorectal cancer have improved survival rates; however, most patients develop resistance to these therapies, creating the need for an active agent to treat patients with advanced disease," said Professor Eric Van Cutsem, M.D., Ph.D., Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium, lead author of the manuscript. "Final results from the first large randomized trial of its kind show that Vectibix provides a benefit in this heavily pre-treated patient population."

The September 2006 Food and Drug Administration (FDA) approval of Vectibix was based on the results from this multi-national, open-label, randomized study of 463 patients. Patients were randomized to receive 6 mg/kg Vectibix plus BSC (n=231) every two weeks or BSC alone (n=232) until disease progression or unacceptable toxicity. An independent, central radiology review board assessed disease progression and tumor shrinkage. BSC patients determined to have disease progression were eligible to cross-over to a separate study and receive Vectibix.

The primary endpoint of this study was an improvement in progression-free survival. Co-secondary study endpoints were best objective response by blinded central review and overall survival time. The effectiveness of Vectibix for the treatment of EGFr
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
2. Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
3. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
4. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
5. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... July 11, 2014  Veran Medical Technologies, ... today the positive, cost-effective final results for ... procedure. The SPiNPerc endobronchial percutaneous biopsy study ... approach to biopsy when a traditional bronchoscopic ... physicians experience positive financial outcomes when more ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
(Date:7/12/2014)... July 12, 2014 As reported in ... of Standards and Technology), the June 25th, 2014 Supreme Court ... discovery world. It was also met with both ... on whether it was seen from an individual privacy perspective, ... is fact, there is now precedent which will require law ...
(Date:7/12/2014)... July 12, 2014 A recent article released ... a trio of suggestions for those seeking cosmetic surgical ... are rapidly approaching and the heat begins to enliven the ... their summer clothing, realizing that they didn’t work out as ... This can cause a sudden surge of people eager to ...
(Date:7/12/2014)... Seattle, Wa (PRWEB) July 12, 2014 ... by Doctors Sen and Samantha Pearson, a couple boasting ... chose to launch Restore My Vision Today as a ... that many ophthalmologists have become in their respective ... makes readers privy to a “secret” trove of pertinent ...
(Date:7/12/2014)... 2014 The largest pure occupational medicine ... to announce that it will be opening its fifth ... will join four Atlanta-based Nova Medical Centers’ locations. The ... Deans Bridge Road, and will be open from 8:30 ... “With Nova’s treatment philosophy of rapid return-to-work and decreased ...
(Date:7/11/2014)... DressyQuinceanera.com, a well-known wedding dress manufacturer and retailer, has ... online category. Furthermore, the firm has announced that all ... to 62% off. , The brand new Quinceanera Dama ... quality and style. All items in the new collection ... the company’s other items: lace evening dresses, short bridesmaid ...
Breaking Medicine News(10 mins):Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2
... (January 25, 2008) Research in the January issue ... (JACS) shows that many patients with minimal injuries ... and II trauma centers, despite the ability of the ... that overuse of trauma centers threatens to limit the ...
... Inc. (NYSE: WTW ) announced today that ... Sardini, Chief Financial,Officer, will present at the Credit ... The presentation will be held on Tuesday, ... a.m. local time) and will be accessible via ...
... to encourage Americans to ... 25 , Who: "The Biggest Loser" Season Four winner Bill Germanakos ... with MSN Health & Fitness and ... discuss "The Biggest Loser" Million Pound Match-Up sweepstakes, at ...
... Doctors Care is,pleased to announce the opening of its ... Hoffmeyer Road, Florence. The new center opened,January 23, 2008. ... scheduled to,open soon., Dr. Thomas Gibbons, the Midlands ... "Doctors Care is excited to provide convenient,urgent care, family ...
... 300-bed facility in Tempe, Arizona, raises MDS capacity in the ... Phoenix-area to 420 ... MDS Pharma,Services (http://www.mdsps.com ), a leading provider of innovative drug ... a new 300-bed Phase I facility in nearby Tempe, Arizona. The ...
... Md., Jan. 25 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... commercializing novel anti-infective products, today,announced that it has ... the private placement of 8,750,000 shares of,its common ... includes,five-year warrants to purchase 3,500,000 shares of common ...
Cached Medicine News:Health News:Excessive overtriage in US trauma centers overwhelming system resources, delaying patient care 2Health News:Weight Watchers to Present at Credit Suisse 10th Annual Global Services Conference 2Health News:Bill Germanakos and Hollie Self Bring 'The Biggest Loser' Million-Pound Tour, Presented by MSN, to Arizona Mills Mall 2Health News:UCI Medical Affiliates Inc. Opens New Doctors Care Center in Florence 2Health News:MDS Pharma Services Opens Largest Phase I Clinic on U.S. West Coast 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 3Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: